-
2024-513077-48-00
5
2024-12-19
O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2024-519113-59-00
4
2024-11-20
Hepatocellular carcinoma
-
2024-514799-42-00
4
2024-11-05
IDIOPATHIC PULMONARY FIBROSIS
-
2024-516394-78-00
5
2024-11-05
Patient with sepsis complicated by ARDS
-
2024-517004-11-00
5
2024-10-22
Chronic pulmonary aspergillosis
-
2024-513219-29-00
5
2024-10-21
Renal Cell Carcinoma
-
2022-502825-17-00
4
2024-10-07
Melanoma
-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
-
2023-504445-31-00
4
2024-09-19
Carcinoma, Head and Neck
-
2023-506227-29-00
3
2024-08-30
locally advanced or metastatic solid tumors
-
2023-509566-38-00
9
2024-08-05
gastroesophageal junction adenocarcinoma
-
2023-503699-25-00
5
2024-07-15
Progressive Pulmonary Fibrosis
-
2024-510741-33-00
4
2024-06-27
Macular degeneration
-
2023-503697-21-01
5
2024-06-24
Idiopathic pulmonary fibrosis
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2023-505486-92-00
4
2024-02-09
Small bowel adenocarcinoma
-
2023-505604-32-00
5
2024-01-24
Non small cell lung cancer (NSCLC)
-
2023-504670-38-00
4
2023-11-17
Extensive disease Small Cell Lung Cancer
-
2022-503058-37-00
5
2023-11-10
Advanced Gastrointestinal Stromal Tumor
-
2022-502959-54-00
5
2023-09-26
Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
-
2022-501904-83-00
7
2023-09-11
Ovarian Cancer
-
2022-502654-14-00
4
2023-09-11
Endometrial cancer
-
2023-504254-35-00
7
2023-06-20
Unresectable locally advanced or metastatic solid tumors:
• Clear cell